Literature DB >> 21757808

Neurological complications following treatment of children with brain tumors.

Michelle Monje1, Paul Graham Fisher.   

Abstract

Brain tumors and their treatments in children result in a range of neurological complications that can affect daily function and rehabilitation potential, including neurocognitive sequelae, ototoxicity, seizure disorders, stroke, and peripheral neuropathy. Deficits in cognitive function, particularly learning and memory, attention and speed of information processing, can be debilitating. With new insights to the cellular and molecular etiology of these deficits, new therapies for cognitive decline after therapy are emerging. Management strategies for other neurological complications are also emerging.

Entities:  

Mesh:

Year:  2011        PMID: 21757808      PMCID: PMC3612581          DOI: 10.3233/PRM-2011-0150

Source DB:  PubMed          Journal:  J Pediatr Rehabil Med        ISSN: 1874-5393


  41 in total

Review 1.  Mechanisms and functional implications of adult neurogenesis.

Authors:  Chunmei Zhao; Wei Deng; Fred H Gage
Journal:  Cell       Date:  2008-02-22       Impact factor: 41.582

2.  Voluntary running rescues adult hippocampal neurogenesis after irradiation of the young mouse brain.

Authors:  Andrew S Naylor; Cecilia Bull; Marie K L Nilsson; Changlian Zhu; Thomas Björk-Eriksson; Peter S Eriksson; Klas Blomgren; H Georg Kuhn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-02       Impact factor: 11.205

3.  Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat.

Authors:  Riejanne Seigers; Sanne B Schagen; Wieteke Beerling; Willem Boogerd; Olaf van Tellingen; Frits S A M van Dam; Jaap M Koolhaas; Bauke Buwalda
Journal:  Behav Brain Res       Date:  2007-08-10       Impact factor: 3.332

4.  Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial.

Authors:  Heather M Conklin; Raja B Khan; Wilburn E Reddick; Susan Helton; Ronald Brown; Scott C Howard; Melanie Bonner; Robbin Christensen; Shengjie Wu; Xiaoping Xiong; Raymond K Mulhern
Journal:  J Pediatr Psychol       Date:  2007-06-14

Review 5.  Cerebrovascular disease in childhood cancer survivors: A Children's Oncology Group Report.

Authors:  B Morris; S Partap; K Yeom; I C Gibbs; P G Fisher; A A King
Journal:  Neurology       Date:  2009-10-07       Impact factor: 9.910

6.  Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.

Authors:  Jennifer B Dean; Susan S Hayashi; Catherine M Albert; Allison A King; Roanne Karzon; Robert J Hayashi
Journal:  J Pediatr Hematol Oncol       Date:  2008-02       Impact factor: 1.289

Review 7.  Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy.

Authors:  Jörg Dietrich; Michelle Monje; Jeffrey Wefel; Christina Meyers
Journal:  Oncologist       Date:  2008-11-19

8.  Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.

Authors:  Claus-Michael Schmidt; Arne Knief; Agatha Katharina Lagosch; Dirk Deuster; Antoinette am Zehnhoff-Dinnesen
Journal:  Ear Hear       Date:  2008-12       Impact factor: 3.570

9.  Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.

Authors:  Gregory T Armstrong; Qi Liu; Yutaka Yasui; Sujuan Huang; Kirsten K Ness; Wendy Leisenring; Melissa M Hudson; Sarah S Donaldson; Allison A King; Marilyn Stovall; Kevin R Krull; Leslie L Robison; Roger J Packer
Journal:  J Natl Cancer Inst       Date:  2009-06-17       Impact factor: 11.816

10.  Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.

Authors:  Ruolan Han; Yin M Yang; Joerg Dietrich; Anne Luebke; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2008-04-22
View more
  6 in total

1.  Low-grade gliomas in children: single institutional experience in 198 cases.

Authors:  Magda Garzón; Gemma García-Fructuoso; Mariona Suñol; Jaume Mora; Ofelia Cruz
Journal:  Childs Nerv Syst       Date:  2015-07-09       Impact factor: 1.475

2.  Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training.

Authors:  Lily Riggs; Janine Piscione; Suzanne Laughlin; Todd Cunningham; Brian W Timmons; Kerry S Courneya; Ute Bartels; Jovanka Skocic; Cynthia de Medeiros; Fang Liu; Nicholas Persadie; Katrin Scheinemann; Nadia Scantlebury; Kamila U Szulc; Eric Bouffet; Donald J Mabbott
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

Review 3.  Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials.

Authors:  Sudarshawn Damodharan; Montserrat Lara-Velazquez; Brooke Carmen Williamsen; Jeffrey Helgager; Mahua Dey
Journal:  J Pers Med       Date:  2022-05-20

4.  Age-Dependent Cellular and Behavioral Deficits Induced by Molecularly Targeted Drugs Are Reversible.

Authors:  Joseph Scafidi; Jonathan Ritter; Brooke M Talbot; Jorge Edwards; Li-Jin Chew; Vittorio Gallo
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

5.  Older age is a protective factor for academic achievements irrespective of treatment modalities for posterior fossa brain tumours in children.

Authors:  Jarmila Kruseova; Anna Sarah Kovacova; Michal Zapotocky; David Sumerauer; Ivana Pernikova; Darja Starkova; Adela Misove; Andrea Zichova; Vaclav Capek; Thorsten Langer; Antoinette Am Zehnhoff-Dinnesen; Tomas Eckschlager; Martin Kyncl
Journal:  PLoS One       Date:  2020-12-16       Impact factor: 3.240

6.  The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.

Authors:  Rogerio B Craveiro; Michael Ehrhardt; Julia Velz; Martin Olschewski; Barbara Goetz; Torsten Pietsch; Dagmar Dilloo
Journal:  Oncotarget       Date:  2017-07-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.